Full-Time

Executive Director

Global Facilities Operations

Posted on 12/1/2025

Deadline 3/17/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$278.6k - $337.6k/yr

+ Incentive cash + Stock opportunities

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

In Person

Category
Facilities Operations (2)
,
Requirements
  • Minimum bachelor’s degree in Engineering, Business, or a related field, MBA preferred
  • 15+ years’ related experience in pharmaceutical engineering and/or facilities operations, with 10+ years of managerial experience
  • Demonstrated enterprise mindset to develop and implement Facilities Management policies and programs
  • Demonstrated understanding of budget forecasting within maintenance and operations environments leveraging industry-standard financial systems and tools to develop achievable OpEx plans that ensure delivery of required services and operational performance to meet business requirements across a diverse, dynamic business landscape
  • Strong experience in facilities technologies and infrastructure systems (HVAC, process, automation, etc.)
  • Strong knowledge of OSHA, NFPA, EPA regulatory requirements desired
  • Strong knowledge of GMP and FDA regulatory requirements desired
  • Demonstrated ability to manage across a diverse workforce including delivering objectives through indirect (outsourced) workforce or in a matrixed organizational model
  • Experience developing and implementing Integrated Facilities Management service delivery model that delivers strong service provider performance through incentives and collaboration
  • Demonstrated ability to create a flexible, multitasking Team capable of delivering challenging objectives
  • Demonstrated written and verbal communication skills
  • A high-level understanding of RCA to ensure that the organization has a culture of continuous improvement
  • Excellent organizational and time management skills
  • Project Management background and/or OpEx Yellow Belt certification desired
  • Demonstrated facilitation skills in a cross-functional, multi-level, matrixed team environment
  • Strong critical reasoning and decision-making skills
  • Ability to absorb multiple inputs in stressful situation and develop a rational plan forward
  • Strategic thinking and ability to work independently
  • Knowledge of common Facilities Management applications and systems including BAS, CMMS, CAFM, etc. as well as Enterprise Systems such as SAP, Ariba, etc.
  • Ability to appropriately manage the interface with regulatory authorities
  • Up to 30% domestic and international travel
Responsibilities
  • Strategic development of Facilities Services for 22 locations in North America, United Kingdom, and Europe
  • Build a vision for the organization culture through amenities provided and services delivered to site occupants. Supports senior leadership in developing strategies for accommodating growth and a dynamic office / research landscape for Research and Development, Global Drug Development, Product Development, Global Pharmaceutical Development and Operations, and Enabling Function departments
  • Collaborate with Global Corporate Services and Corporate Real Estate/Workplace Services on determining future space requirements versus current capacities as part of site and regional Master Planning. Identify innovative solutions that optimize square footage requirements to meet a very dynamic business environment, including leading site divestitures efforts or supporting new business development integration activities
  • Champion the use of innovative digital tools and technologies to elevate operational excellence in the delivery, management, and monitoring of Facilities Services. Implement Sustainability programs across the global footprint in partnership with Corporate Environmental Health and Safety and Sustainability that support Bristol Myers Squibb’s company goals and objectives
  • With the GFO Leadership Team, develop internal and external capabilities needed to drive efficient performance and elevate GFO value proposition to our key stakeholders. Continuously refine the GFO KPI Dashboard to correctly reflect priorities and areas of transformation
  • Collaborate with site Leadership Teams across the portfolio to strengthen the relation and open communication with local authorities. Also ensure strategic integration and communications with the local community to create a positive image of the company
  • Develop site level Capital Strategic Plans, coordinating with Global Corporate Services and key site stakeholders to ensure future requirements and business needs can be met. Prioritize master planning initiatives across the portfolio to direct resources as business focus dictates
  • Develop, in collaboration with Strategic Sourcing and Operations, Legal and Finance Business Partners, the short and long-term strategies for the Integrated Facilities Management Service Delivery Model globally. Ensure the execution of these strategies and plans to enable the success of the IFM Model for all in-scope services categories
  • Development and implementation of global IFM strategies and approaches to fulfill global, regional, or site level service requirements regardless of size and complexity
  • Foster a strong culture of collaboration with the IFM Service Provider across GTS sites as well as non-GTS manufacturing facilities. This includes a broad range of services from typical soft services (e.g., housekeeping, hospitality services, landscaping) to Facilities Maintenance & Utilities Operations, Security Services and various Laboratory Services
  • Lead with a global mindset to develop innovative strategies for delivering safe, effective Facilities and Environmental Health and Safety Services that help site customers deliver for our patients
  • Lead and serve as the role model for an organizational culture that embraces respect and collaboration, passion and engagement, trust, integrity and accountability, innovation and growth, quality, productivity and continuous improvement
  • Advocate for discipline excellence by partnering closely with internal and external stakeholders to improve customer service and develop and cultivate industry-competitive best practices
  • Influence enterprise-wide business decisions through the on-going leadership of employee amenities, OpEx and CapEx spending plans and collaboration with enterprise People and Business Resource Groups leads
  • Collaborate with the Executive Director Global Capital Project Engineering to ensure successful implementation of strategic capital investments across the GTS site portfolio
  • Drive complex communications that are efficient, effective and timely. Ensure that all customers are fully informed and knowledgeable of Facilities Management activities. This includes communications with site leadership and Bristol Myers Squibb Leadership at headquarters sites
  • Ownership of the GFO $700M+ OpEx budget including collaborating with the GTS Leadership Team to manage within +/- 5%
  • Ensure that all Facilities meet government regulations and environmental, health and safety, and security standards. Collaborate with Corporate EHSS to develop and deliver sustainability programs like Water and energy savings Initiatives as well as Carbon Neutrality through Scope 1 and Scope 2 GHG emissions by 2040
  • Collaborate with EHSS and Engineering on the broader commitment to reach net-zero GHG emissions by 2050
  • Promote safe practices and behaviors, verify Corporate EHSS Standards are implemented and respected
Desired Qualifications
  • None

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

INACTIVE